Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463795 | 1.00 | SIGMAR1 (0.72) | SIGMAR1KDM4EALDH1A1CHRM3GAA | |
| Hydrochloric Acid SCHEMBL7422123 | 0.98 | SIGMAR1 (0.70) | SIGMAR1KDM4EALDH1A1CHRM3GAA | |
| SCHEMBL1382022 | 0.98 | SIGMAR1 (0.70) | SIGMAR1KDM4EALDH1A1CHRM3GAA | |
| SCHEMBL17696031 | 0.94 | SIGMAR1 (0.65) | SIGMAR1KDM4EALDH1A1CHRM3GAA | |
| Hydrochloric Acid SCHEMBL7424646 | 0.93 | SIGMAR1 (0.63) | SIGMAR1KDM4EALDH1A1CHRM3GAA | |
| SCHEMBL28186295 | 0.89 | SIGMAR1 (0.90) | SIGMAR1KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL20804357 | 0.89 | SIGMAR1 (0.90) | SIGMAR1KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL30774908 | 0.85 | SIGMAR1 (0.79) | SIGMAR1KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL3162705 | 0.85 | SIGMAR1 (0.79) | SIGMAR1KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL6498878 | 0.85 | CCR8 (0.59) | SIGMAR1KDM4EALDH1A1CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| CN-117069686-A | Genipin derivative, preparation method and application thereof | 安徽中医药大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| CN-110615774-B | Benzyl piperazine compound with anti-inflammatory activity, preparation method and medical application | 安徽中医药大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5219857-A | Method of treating cognitive and related neural behavioral problems | AMERICAN CYANAMID COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0533516-A2 | Amides of 1-(alkoxybenzyl)piperazines, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-03-24 | — | — | EP | disclosed |
| US-5126340-A | Antidepressants | AMERICAN CYANAMID COMPANY (US) | 1992-06-30 | — | — | US | disclosed |
| US-4963553-A | TREATING COGNITIVE AND NEURAL BEHAVIORAL PROBLEMS IN MAMMALS | AMERICAN CYANAMID CO. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4940793-A | Pharmacologically active piperazino derivatives | RAVIZZA S.P.A. (IT) | 1990-07-10 | — | — | US | disclosed |
| EP-0171636-A1 | Pharmacologically active piperazino derivatives and the process for their preparation | RAVIZZA S.p.A. (IT) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | SIGMAR1 480/4885KDM4E 2981/4885ALDH1A1 1731/4885 |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | LMNB2, LMNB1, TPX2 | SIGMAR1 1454/4885KDM4E 2133/4885ALDH1A1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.